Several scientific studies have shown that the long-term prognosis of patients with coronary artery disease is unsatisfactory, with a high rate of recurrence of cardiovascular and cerebrovascular events (myocardial infarction or other acute coronary syndromes, ischemic stroke/transient ischemic attack, peripheral arterial disease). Therefore, it is particularly important to manage blood lipids (mainly LDL-C) in a standardized manner. LDL-C levels are linearly related to the progression of atherosclerosis, and the lower the LDL-C, the more plaque progression tends to be slowed down or even reversed. The latest European guidelines recommend LDL-C to <1.4 mmol/L. Further, the longer the LDL-C reduction is maintained, the greater the benefit: a 1 mmol/L reduction in LDL-C is associated with a 22% reduction in the risk of ASCVD at 5 years, a 28% reduction at 10 years, and a 54% reduction at 40 years, while a 2 mmo/L reduction in LDL-C is associated with a 39% reduction in the risk of ASCVD at 5 years, a 48% reduction at 10 years, and a 79% reduction at 40 years. 48% lower, and 79% lower at 40 years. It is suggested that the lower the LDL-C, the longer the maintenance time, the greater the benefit. For this reason, statins, as the preferred lipid regulators, reduce the occurrence and progression of adverse cardiovascular events by inhibiting cholesterol synthesis, stabilizing plaque, and reducing plaque progression. Therefore, patients with coronary artery disease need to standardize and meet the standard of medication under the guidance of doctors in order to improve the quality of life and improve the prognosis. To this end, statins, as the preferred lipid regulators, stabilize plaque by inhibiting cholesterol synthesis, reduce plaque progression, and reduce the occurrence and progression of adverse cardiovascular events. Therefore, patients with coronary artery disease need to standardize and meet the standard of medication under the guidance of doctors in order to improve the quality of life and improve the prognosis.